Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... GLP-1 agonist drugs Ozempic for diabetes and Wegovy for obesity – suggests "the company may ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

The new vials – priced at $399 and ... way ahead of forecasts – at the same time as Novo Nordisk has reported the first signs of weaker growth for Wegovy. The new launch has caught the ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

The Danish pharma giant, known for its blockbuster diabetes and weight-loss medications Ozempic and Wegovy, is on track to have its worst week on Wall Street this year. Novo Nordisk shares have ...

The company's famous medicines, diabetes treatment Ozempic and anti-obesity medicine Wegovy, have been on fire. However, some investors are worried that Novo Nordisk will lose significant market ...

Novo Nordisk's sales and profits were both up around ... with the company's GLP-1 weight loss treatment, Wegovy, more than doubling its sales during the period. The company is expecting a more ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE ... company's GLP-1 weight loss treatment, Wegovy, more than doubling its sales ...